Degryse S.,Center for the Biology of the Disease |
Degryse S.,Catholic University of Leuven |
Cools J.,Center for the Biology of the Disease |
Cools J.,Catholic University of Leuven
Journal of Hematology and Oncology | Year: 2015
Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias. © 2015 Degryse and Cools.